Advertisement

Topics

Kensey Nash Corporation Company Profile

17:46 EST 16th November 2018 | BioPortfolio


News Articles [362 Associated News Articles listed on BioPortfolio]

Is NASH Really a $35 Billion Opportunity?

Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalc...

Drs. Jonathan and Kenneth Nash Treat Gum Disease in Vicksburg, MS with Modern Laser Dentistry, Honor National Gum Care Month

VICKSBURG, MS (PRWEB) September 13, 2018 Nash Family Dentistry team, Drs. Jonathan Nash and Kenneth Nash, are honoring National Gum ...

Novartis, Pfizer Partner for NASH

A complex condition with no available treatment options, NASH affects up to 6.5% of the population worldwide

New partners for NASH

This year’s AASLD Liver meeting contains data on new NASH mechanisms for pharmas to consider picking up, but little clarity on combination strategy.

NASH Cirrhosis: The Real NASH Epidemic

First International NASH Day is a Call to Action

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease ...

The European Fight Against NASH, The Silent Liver Disease

Today is the First International NASH Day, and to mark the occasion, we bring you an update on Europe’s efforts to tackle this largely unrecognized liver disease that currently has no treatment and ...

NASH drugs come into focus as field awaits late-stage data

This year's Liver Meeting could shift the fortunes for a second wave of NASH-focused biotechs advancing behind the four drugmakers currently out in front.

PubMed Articles [120 Associated PubMed Articles listed on BioPortfolio]

Nonalcoholic steatohepatitis in posttransplantation liver: Review article.

Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and ...

Treatment of NASH with Gastric Bypass.

Nonalcoholic steatohepatitis (NASH) is a spectrum of nonalcoholic fatty liver disease (NAFLD). It is defined as the presence of fatty liver along with inflammation and hepatocyte injury. To date, weig...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

The future R&D landscape in non-alcoholic steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue for the 21st century and is associated with significant liver-related morbidity and mortality. At present, there are no a...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Clinical Trials [166 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [207 Associated Companies listed on BioPortfolio]

Kensey Nash Corp.

Kensey Nash Corporation

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occlud...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

More Information about "Kensey Nash Corporation" on BioPortfolio

We have published hundreds of Kensey Nash Corporation news stories on BioPortfolio along with dozens of Kensey Nash Corporation Clinical Trials and PubMed Articles about Kensey Nash Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kensey Nash Corporation Companies in our database. You can also find out about relevant Kensey Nash Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record